Healthcare / Medical DevicesNasdaqCM
$3.94
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.8M · quality 61.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
24/100
D
Piotroski
5/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$789M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-31.7%
↓Gross Margin
46.0%
↓Debt/Equity
0.38
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2016–2025 · 9 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-52.3%
FCF / Net income
1.83x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $42.5M · net income $-12.1M · FCF $-22.2M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | $42.5M | $42.5M | $20.6M | $5.9M | $1.4M | — | — | — | — | — | — |
| Net Income | $-12.1M | $-12.1M | $-19.2M | $-20.9M | $-3.2M | $-1.5M | $-1.1M | $-3.4M | $-960322.00 | $-1.0M | $-484982.00 |
| EBITDA | $-6.0M | $-6.0M | $-17.7M | $-19.8M | $-2.9M | — | — | — | — | — | — |
| EPS | -0.06 | -0.06 | -0.11 | -0.14 | -0.03 | -0.05 | -0.05 | -0.16 | — | — | — |
| Gross Margin | 46.0% | 46.0% | 40.9% | 12.3% | 4.2% | — | — | — | — | — | — |
| Operating Margin | -19.3% | -19.3% | -91.9% | -345.1% | -206.0% | — | — | — | — | — | — |
| Net Margin | -28.5% | -28.5% | -92.7% | -355.4% | -223.8% | — | — | — | — | — | — |
| Balance Sheet | |||||||||||
| Debt/Equity | 0.38 | 0.38 | 1.35 | 0.47 | -3.09 | — | — | — | — | — | — |
| Current Ratio | 2.54 | 2.54 | — | — | — | — | — | — | — | — | — |
| Cash Flow | |||||||||||
| Free Cash Flow | $-22.2M | $-22.2M | $-10.2M | $-15.8M | $-6.0M | — | — | — | — | — | — |
| Returns | |||||||||||
| ROE | -31.7% | -31.7% | -142.3% | -105.9% | 120.0% | -253.5% | 129.4% | 318.5% | 430.6% | -1026.5% | 136.6% |
| Valuation | |||||||||||
| P/B | 20.48 | 20.48 | 105.03 | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||
| Revenue Growth | 105.7% | 105.7% | 251.5% | 309.1% | — | — | — | — | — | — | — |
| EPS Growth | 45.5% | 45.5% | 21.4% | -366.7% | — | 0.0% | 68.8% | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-37.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → -0.06
Residual
-37.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.